+22.5% in one quarter: Sartorius Stedim Biotech stock gains 2%
Sartorius Stedim Biotech rebounds mid-session, as the SBF 120 advances sharply. The stock erases part of its decline from the previous day and climbs back toward the resistance zone it had reached in early October, following a very strong quarter.
A rebound that places the stock above its three moving averages
The Sartorius Stedim Biotech stock gains 2.02% to €212.20, in a rising Paris market: the CAC 40 advances 0.84% and the SBF 120 by 0.88%. Today's gain only offsets a fraction of the 11.45% increase accumulated over one month, and the stock approaches the resistance level at €218.80, which the previous session had already tested. The price remains above the MA20 (3.35% difference), the MA50 (9.82%) and the MA200 (16.39%). The more than 16% gap with the MA200 demonstrates the significant ground covered since the summer, with an RSI at 55 that shows nothing excessive despite this advance.
A stock valued at 42.5 times expected earnings for the current fiscal year
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Based on expected earnings per share, the stock trades at approximately 42.5 times the earnings of the current fiscal year and 35.3 times those of the following fiscal year, according to analyst consensus. Following the publication of the first half of 2026 on July 22, the group had confirmed its annual targets. Over three months, the stock gains 22.38%, compared to 9.95% over one year. The next level to monitor is the resistance at €218.80, which the stock is now 3.1% away from.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1 527 millions d'euros
Quarterly revenue: 1 527 millions d'euros
EBITDA: 463,7 millions d'euros
EBITDA margin: 31,4 %
Net income: 181,1 millions d'euros
2 199 millions d'euros
Outlook / guidance
Expected revenue: 3 154 millions d'euros
Expected EBITDA: 989,2 millions d'euros
Management commentary: Sartorius Stedim Biotech continue de prévoir une croissance du chiffre d'affaires à taux de change constant d'environ 6 à 10 %.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
